An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

Herold, Kevan C., Bundy, Brian N., Long, S. Alice, Bluestone, Jeffrey A., DiMeglio, Linda A., Dufort, Matthew J., Gitelman, Stephen E., Gottlieb, Peter A., Krischer, Jeffrey P., Linsley, Peter S., Marks, Jennifer B., Moore, Wayne, Moran, Antoinette, Rodriguez, Henry, Russell, William E., Schatz, Desmond, Skyler, Jay S., Tsalikian, Eva, Wherrett, Diane K., Ziegler, Anette-Gabriele, Greenbaum, Carla J.·2019·New England Journal of Medicine
DOI 10.1056/nejmoa1902226

Cited by (1,000)

Items 501–600 of 1,000

  1. Advances in the Use of Biologics and Biomaterials toward the Improvement of Pancreatic Islet Graft Survival in Type 1 Diabetes
    Michael Yilma Yitayew, Marina Luginina, Maryam Tabrizian · 2024 · Advanced NanoBiomed Research
  2. Real‐world experiences of adult individuals or caregivers of children who received teplizumab treatment in stage 2 type 1 diabetes
    Holly K. O’Donnell, Kimber M. Simmons, Stephen Eric Gitelman, TERRY A. DEX, Robert Graham Hill, Mattias Wieloch, JULIA H. ZACCAI, Jennifer D'Souza, France Ginchereau Sowell, James D. Turnbull et al. · 2025 · Diabetes Obesity and Metabolism
  3. 100 YEARS OF INSULIN: Arresting or curing type 1 diabetes: an elusive goal, but closing the gap
    Pieter-Jan Martens, Conny A. Gysemans, Chantal Mathieu · 2021 · Journal of Endocrinology
  4. Tolerance induction by liposomes targeting a single CD8 epitope IGRP206–214 in a model of type 1 diabetes is impeded by co‐targeting a CD4+ islet epitope
    Irina Buckle, Jeniffer D Loaiza Naranjo, Anne‐Sophie Bergot, Vivian Zhang, Meghna Talekar, Raymond John Steptoe, Ranjeny Thomas, Emma E. Hamilton‐Williams · 2021 · Immunology and Cell Biology
  5. Cost-Effectiveness of Low-Dose Antithymocyte Globulin Versus Other Immunotherapies for Treatment of New-Onset Type 1 Diabetes
    Hai V. Nguyen, Desmond Schatz, Shweta Mital, Laura M. Jacobsen, Michael J. Haller · 2021 · Diabetes Technology & Therapeutics
  6. Tolerance Induced by Antigen-Loaded PLG Nanoparticles Affects the Phenotype and Trafficking of Transgenic CD4+ and CD8+ T Cells
    Tobias Neef, Igal Ifergan, Sara A. Beddow, Pablo Penaloza‐MacMaster, KATHRYN M. HASKINS, Lonnie D. Shea, Joseph R. Podojil, Stephen D. Miller · 2021 · Cells
  7. Celebration of a century of insulin therapy in children with type 1 diabetes
    Alan David Rogol, Lori M. Laffel, Bruce W. Bode, Mark A. Sperling · 2022 · Archives of Disease in Childhood
  8. Clinical and experimental treatment of type 1 diabetes
    Sarah Alice Long, Jane Hoyt Buckner · 2022 · Clinical & Experimental Immunology
  9. Translational immunology: Applying fundamental discoveries to human health and autoimmune diseases
    Jane Hoyt Buckner · 2023 · European Journal of Immunology
  10. A Question of Tolerance—Antigen-Specific Immunotherapy for Type 1 Diabetes
    Jeniffer D Loaiza Naranjo, Anne‐Sophie Bergot, Irina Buckle, Emma E. Hamilton‐Williams · 2020 · Current Diabetes Reports
  11. The extra-islet pancreas supports autoimmunity in human type 1 diabetes
    Graham L. Barlow, Christian M. Schürch, Salil S. Bhate, Darci J. Phillips, Arabella Young, Shen Dong, Hunter A. Martinez, Gernot Kaber, Nadine Nagy, Sasvath Ramachandran et al. · 2024 · eLife
  12. Prevention and treatment of type 1 diabetes: in search of the ideal combination therapy targeting multiple immunometabolic pathways
    Marcelo Maia Pinheiro, Felipe Moura Maia Pinheiro, Maria Luisa Garo, Donatella Pastore, Francesca Pacifici, Camillo Ricordi, David Della‐Morte, Marco Infante · 2024 · Metabolism and Target Organ Damage
  13. Immunotherapy-Based Strategies for Treatment of Type 1 Diabetes
    Laura M. Jacobsen, Desmond Schatz · 2024 · Hormone Research in Paediatrics
  14. Preclinical characterization of MTX-101: a novel bispecific CD8 Treg modulator that restores CD8 Treg functions to suppress pathogenic T cells in autoimmune diseases
    Jennifer L. Gardell, Meghan E. Maurer, Monica M. Childs, Minh Nguyet Pham, Brent Meengs, Susan H. Julien, Cong Tan, Daniel R. Boster, Phoenicia Quach, Jon Henry Therriault et al. · 2024 · Frontiers in Immunology
  15. Targeted Therapies: The Role of Monoclonal Antibodies in Disease Management
    Akram N. Salah, Amr Hosny Hashem, Mohamed Bakr Zaki, Ahmed I. Abulsoud, Asmaa M. Atta, Wagiha S. Elkalla, Hebatallah Ahmed Mohamed Moustafa, Walaa A. El‐Dakroury, Fatma Sa’eed El-Tokhy, Jasmine A. ElBoghdady et al. · 2025 · Journal of Biochemical and Molecular Toxicology
  16. A Cure for Type 1 Diabetes: Are We There Yet?
    Chris Schaaf, Lori Sussel · 2025 · Diabetes Technology & Therapeutics
  17. Renalase inhibition defends against acute and chronic β cell stress by regulating cell metabolism
    Tara L. MacDonald, Birgitta A. Ryback, Jéssica Aparecida da Silva Pereira, Siying Wei, Bryhan Mendez, Erica P. Cai, Yuki Ishikawa, Meagan Arbeau, Gordon C. Weir, Susan Bonner‐Weir et al. · 2025 · Molecular Metabolism
  18. A Comparative Evaluation of the Chemiluminescence Immunoassay and ELISA for the Detection of Islet Autoantibodies in Type 1 Diabetes
    Elisa Danese, Claudia Anita Piona, Mariateresa Rizza, Elena Tiziani, Laura Pighi, Elisa Morotti, Gian Luca Salvagno, Camilla Mattiuzzi, Claudio Maffeis, Giuseppe Lippi · 2025 · Diagnostics
  19. Imbalance of stem-like and effector T cell states in children with early type 1 diabetes across conventional and regulatory subsets
    Veronika Niederlová, Aleš Neuwirth, Vít Neuman, Juraj Michalik, Bela Charvatova, Martin Modrák, Zdenĕk Šumnı́k, Ondřej Štěpánek · 2025 · Nature Communications
  20. Continuous glucose monitoring as a tool in early-stage type 1 diabetes
    Alice L. J. Carr, Hannah Sutton, Rikke Mette Agesen, Ezio Bonifacio, Emanuele Bosi, Pieter Gillard, Rabbi Swaby, Jurgen Vercauteren, Rachel E.J. Besser · 2026 · Diabetologia
  21. Screening Children for Early-Stage Type 1 Diabetes
    Christiane Winkler, Nadine Friedl, Renate Abt, Kathrin Ackermann, Julia Bently, Sonja Braig, Susanne Brämswig, Désirée Dunstheimer, Uwe Ermer, Dominik Ewald et al. · 2026 · JAMA
  22. Imaging mass cytometry reveals functional and immunological changes during type 1 diabetes progression in human pancreata
    Nathan Steenbuck, Nicolas Damond, Stefanie Engler, Irina Kusmartseva, Amanda L. Posgai, Denise Minerva Drotar, MacKenzie D. Williams, Natalie de Souza, Todd M. Brusko, Maigan Brusko et al. · 2026 · Nature Metabolism
  23. Teplizumab Therapy to Delay the Onset of Type 1 Diabetes
    Joel Novograd, William H. Frishman · 2023 · Cardiology in Review
  24. Sex-oriented perspectives in immunopharmacology
    Andrea Cignarella, Elisabetta Vegeto, Chiara Bolego, Luigia Trabace, Lucia Conti, Elena Ortona · 2023 · Pharmacological Research
  25. Pharmaceutical targeting of the cannabinoid type 1 receptor impacts the crosstalk between immune cells and islets to reduce insulitis in humans
    Elise Wreven, María Soledad Ruiz de Adana, Stephan Hardivillé, Valéry Gmyr, Julie A. Kerr-Conte, Mikaël Chetboun, Gianni Pasquetti, Nathalie Delalleau, Julien Thévenet, Anaïs Coddeville et al. · 2024 · Diabetologia
  26. Single-cell analysis reveals islet autoantigen’s immune activation in type 1 diabetes patients
    Takuro Okamura, Noriyuki Kitagawa, Nobuko Kitagawa, Kimiko Sakai, Madoka Sumi, Genki Kobayashi, Dan Imai, Takaaki Matsui, Masahide Hamaguchi, Michiaki Fukui · 2024 · Journal of Clinical Biochemistry and Nutrition
  27. Shortening the paths to type 1 diabetes mellitus prevention
    Anette‐Gabriele Ziegler, Ezio E. Bonifacio · 2020 · Nature Reviews Endocrinology
  28. Immunotherapeutic Strategies in Cancer and Atherosclerosis—Two Sides of the Same Coin
    Felix Sebastian Nettersheim, Felix S.R. Picard, Friedrich Felix Hoyer, Holger Winkels · 2022 · Frontiers in Cardiovascular Medicine
  29. Diabetes Mellitus
    Mark A. Sperling, Joseph I. Wolfsdorf, Ram K. Menon, William V. Tamborlane, David M. Maahs, Tadej Battelino, Moshe Phillip · 2021 · Elsevier eBooks
  30. The Transition From a Compensatory Increase to a Decrease in C-peptide During the Progression to Type 1 Diabetes and Its Relation to Risk
    Heba M. Ismail, David D Cuthbertson, Stephen Eric Gitelman, Jay S. Skyler, Andrea K. Steck, Henry Rodriguez, Mark A. Atkinson, Brandon M. Nathan, MARIA JOSE REDONDO, Kevan C. Herold et al. · 2022 · Diabetes Care
  31. What does the licensing of teplizumab mean for diabetes care?
    Lauren Marie Quinn, Rabbi Swaby, Danijela Tatović, Parth Narendran, Rachel E.J. Besser, Colin Mark Dayan · 2023 · Diabetes Obesity and Metabolism
  32. Leveraging type 1 diabetes human genetic and genomic data in the T1D knowledge portal
    Parul Kudtarkar, Maria C. Costanzo, Ying Sun, Dongkeun Jang, Ryan Koesterer, Josyf C. Mychaleckyj, Uma Nayak, Suna Önengüt-Gümüşcü, Stephen S. Rich, Jason A. Flannick et al. · 2023 · PLoS Biology
  33. Reversal of Experimental Autoimmune Diabetes With an sCD39/Anti-CD3 Treatment
    Carmen Fotino, Ruth Damaris Molano, Moufida Ben Nasr, Oliver Umland, Christopher A. Fraker, Ulisse Ulissi, Hari Baskar Balasubramanian, Maria Elena Lunati, Vera Usuelli, Andy Joe Seelam et al. · 2023 · Diabetes
  34. Controversies in medicine: redefining the diagnosis of type 1 diabetes
    Jennifer Couper, Leonard C. Harrison · 2019 · The Medical Journal of Australia
  35. Single-Cell Analysis of CD4 T Cells in Type 1 Diabetes: From Mouse to Man, How to Perform Mechanistic Studies
    Siddhartha M. Sharma, Jeremy Pettus, Michael Everett Gottschalk, Brian T. Abe, Peter A. Gottlieb, Luc Teyton · 2019 · Diabetes
  36. Precision Diagnostics: Using Islet Autoantibodies to Characterize Heterogeneity in Type 1 Diabetes
    Jamie Lynn Felton, MARIA JOSE REDONDO, Richard A. Oram, Cate Speake, Sarah Alice Long, Suna Önengüt-Gümüşcü, Stephen S. Rich, Gabriela S. F. Monaco, Arianna Harris-Kawano, Dianna Perez et al. · 2023 · medRxiv
  37. Immunotherapy in type 1 diabetes: Novel pathway to the future ahead
    Sayantan Ray, Rajan Palui · 2024 · World Journal of Diabetes
  38. Immunometabolic biomarkers for partial remission in type 1 diabetes mellitus
    Laia Gómez-Muñoz, Juan Domínguez‐Bendala, Ricardo Luis Pastori, Marta Vives‐Pi · 2023 · Trends in Endocrinology and Metabolism
  39. Factors Governing B Cell Recognition of Autoantigen and Function in Type 1 Diabetes
    Lindsay E Bass, Rachel H. Bonami · 2024 · Antibodies
  40. Small-molecule inhibitors of the CD40–CD40L costimulatory interaction are effective in pancreatic islet transplantation and prevention of type 1 diabetes models
    Sung-Ting Chuang, Oscar Alcazar, B.M. Watts, Midhat H. Abdulreda, Péter Buchwald · 2024 · Frontiers in Immunology
  41. Pharmacotherapeutic strategies to promote regulatory T cell function in autoimmunity
    Robert C Wright, Daniel Campbell, Megan K. Levings · 2025 · Current Opinion in Immunology
  42. Molecular and Inflammatory Etiologies of β-Cell Dysfunction in Type 1 Diabetes
    Cameron R. Rostron, Carmella Evans‐Molina · 2025 · Physiology
  43. Advances in Regulatory Cell Therapy for Type 1 Diabetes: Emerging Strategies and Future Directions
    Laura Passerini, Aurora Forlani, Silvia Gregori · 2025 · European Journal of Immunology
  44. Latent EBV enhances the efficacy of anti-CD3 mAb in Type 1 diabetes
    Ana Lledó-Delgado, Paula Preston‐Hurlburt, Lauren E. Higdon, Alex K. Hu, Eddie A. James, Noha Lim, Sarah Alice Long, James McNamara, Hai Dang Nguyen, Elisavet Serti et al. · 2025 · Nature Communications
  45. Development and recalibration of a multivariable type 1 diabetes prediction model for type 1 diabetes across multiple screening studies
    Erin L. Templeman, Lauric A. Ferrat, Hemang M. Parikh, Lu You, Taylor M. Triolo, Andrea K. Steck, William Hagopian, Kendra Vehik, Suna Önengüt-Gümüşcü, Peter A. Gottlieb et al. · 2025 · BMC Medicine
  46. The Heterogeneity of Type 1 Diabetes: Implications for Pathogenesis, Prevention, and Treatment—2024 Diabetes , Diabetes Care , and Diabetologia Expert Forum
    Carmella Evans‐Molina, Yuval Dor, Åke Lernmark, Chantal Mathieu, Jeffrey R. Millman, Raghavendra G. Mirmira, Flemming Pociot, MARIA JOSE REDONDO, Stephen S. Rich, Sarah J. Richardson et al. · 2025 · Diabetes
  47. Monocyte/macrophage-derived interleukin-15 mediates the pro-inflammatory phenotype of CD226+ B cells in type 1 diabetes
    J.L. Li, Xin Liang, Mingjiu Zhao, Wenjun Luo, Juan Huang, Yang Xiao, Jiaqi Huang, Bin Zhao, Zhiguang Zhou · 2025 · EBioMedicine
  48. Teplizumab for stage 2 type 1 diabetes: a new era in pediatric diabetes prevention
    Doaa Zaitoon, Hussein Zaitoon · 2025 · European Journal of Pediatrics
  49. Adult-onset type 1 diabetes: early detection, differential diagnosis, and emerging disease-modifying therapies
    Robert J. Wagner, Martin Füchtenbusch, Michael Hummel, Martin Miszon, Andreas Pfützner, Susanne Tan, Tobias Wiesner · 2025 · Diabetes Research and Clinical Practice
  50. Effect of High-Dose Oral Insulin in Children With Stage 1 Type 1 Diabetes: The Fr1da Insulin Intervention Randomized Controlled Trial
    Anette‐Gabriele Ziegler, Ali Albeer, Stefanie Arnolds, Robin Assfalg, Melanie Bunk, Carolin Daniel, Anna Hofelich, Stefanie Jacobsen, Kerstin Kick, Jan Knoop et al. · 2026 · Diabetes Care
  51. Everyone or Just Some? Cost-Effectiveness of General Population Versus Targeted Screening Strategies for Type 1 Diabetes in Canada
    Shweta Mital, Desmond Schatz, Michael J. Haller, Diane K. Wherrett, Hai V. Nguyen · 2026 · Diabetes Care
  52. Beyond bystanders: How β cell stress shapes the autoimmune response in T1D
    Feyza Engin, Decio Laks Eizirik · 2026 · Science Translational Medicine
  53. Stem-Cell-Derived β-Like Cells with a Functional PTPN2 Knockout Display Increased Immunogenicity
    Taylor M. Triolo, J. Quinn Matuschek, Roberto Castro-Gutiérrez, Ali H. Shilleh, Shane P. M. Williams, Maria S. Hansen, Kristen A. McDaniel, Jessie M. Barra, Aaron W. Michels, Holger A. Russ · 2022 · Cells
  54. The Etiological Diagnosis of Diabetes: Still a Challenge for the Clinician
    Danièle Dubois‐Laforgue, José Timsit · 2023 · Endocrines
  55. Islet cells in human type 1 diabetes: from recent advances to novel therapies – a symposium-based roadmap for future research
    James Cantley, Decio Laks Eizirik, Esther Latres, Colin Mark Dayan, _ _ · 2023 · Journal of Endocrinology
  56. Journey of Teplizumab: A Promising Drug in the Treatment of Type 1 Diabetes Mellitus
    Nikita Sharma, Debashree Debasish Das, Pooja A. Chawla · 2024 · Current Diabetes Reviews
  57. Immune checkpoint modulators in early clinical development for the treatment of type 1 diabetes
    E. Maddaloni, Rocco Amendolara, Angela Balena, Alessandro Latino, Rosario Luigi Sessa, R. Buzzetti · 2024 · Expert Opinion on Investigational Drugs
  58. Are we ready to screen for type 1 diabetes? A structured worldwide survey among healthcare providers involved in paediatric diabetes care
    Vít Neuman, Claudia Anita Piona, Laura Cudizio, Lenka Drnkova, Zdenĕk Šumnı́k, Matvei G. Slavenko, Michael J. Haller, David M. Maahs, Agata P Chobot, the ISPAD Jenious Group · 2024 · Diabetic Medicine
  59. From pre-clinical efficacy to promising clinical trials that delay Type 1 diabetes
    J. Jason Collier, Daniel S. Hsia, Susan J. Burke · 2024 · Pharmacological Research
  60. Evolving Concepts in Pathophysiology, Screening, and Prevention of Type 1 Diabetes: Report of Diabetes Mellitus Interagency Coordinating Committee Workshop
    Carla J. Greenbaum, Gerald T. Nepom, Lauren K. Wood Heickman, Diane K. Wherrett, Linda Anne DiMeglio, Kevan C. Herold, Jeffrey P. Krischer · 2024 · Diabetes
  61. Genetic evidence for efficacy of targeting IL-2, IL-6 and TYK2 signalling in the prevention of type 1 diabetes: a Mendelian randomisation study
    Tea E Heikkilä, E. Kaiser, Jake Lin, Dipender Gill, Jaakko J. Koskenniemi, Ville Karhunen · 2024 · Diabetologia
  62. Identifying Promising Immunomodulators for Type 1 Diabetes (T1D) and Islet Transplantation
    Nida Ajmal, Maislin C. Bogart, Palwasha Khan, Ibiagbani M. Max-Harry, Amber M. Healy, Craig S. Nunemaker · 2024 · Journal of Diabetes Research
  63. Phenotypic and Genetic Diversity in Diabetes Across Populations
    Aaron J. Deutsch, Miriam S. Udler · 2025 · The Journal of Clinical Endocrinology & Metabolism
  64. The Unfavorable Impact of DR9/DR9 Genotype on the Frequency and Quality of Partial Remission in Type 1 Diabetes
    Yan Chen, Ying Xia, Zhiguo Xie, Ting Zhong, Rong Tang, Xia Li, Zhiguang Zhou · 2021 · The Journal of Clinical Endocrinology & Metabolism
  65. Mistaken Identity: The Role of Autoantibodies in Endocrine Disease
    Heather A. Nelson, Hemant R Joshi, Joely A. Straseski · 2021 · The Journal of Applied Laboratory Medicine
  66. Preparation and In Vitro Evaluation of RITUXfab-Decorated Lipoplexes to Improve Delivery of siRNA Targeting C1858T PTPN22 Variant in B Lymphocytes
    Andrea Arena, Eugenia Belcastro, Antonella Accardo, Annamaria Sandomenico, Olivia Pagliarosi, Elisabetta Rosa, Stefania Petrini, Libenzio Adrian Conti, Ezio Giorda, Tiziana Corsetti et al. · 2021 · International Journal of Molecular Sciences
  67. A centennial review of discoveries and advances in diabetes: Children and youth
    Sejal Mistry, Ksenia N. Tonyushkina, Valeria C. Benavides, Abha Choudhary, Lina Huerta‐Saenz, Neha S. Patel, Farid H. Mahmud, Ingrid M. Libman, Mark A. Sperling · 2022 · Pediatric Diabetes
  68. C-peptide Targets and Patient-centered Outcomes of Relevance to Cellular Transplantation for Diabetes
    Kevin K. Verhoeff, Braulio A. Marfil‐Garza, Khaled Z. Dajani, David L. Bigam, Blaire L. Anderson, Tatsuya Kin, Anna P. Lam, Doug O’Gorman, Peter Alexander Senior, Andrew M. James Shapiro · 2022 · Transplantation
  69. Re-Enlightenment of Fulminant Type 1 Diabetes under the COVID-19 Pandemic
    Hiroyuki Sano, Akihisa Imagawa · 2022 · Biology
  70. Suppression of anti-drug antibody formation against coagulation factor VIII by oral delivery of anti-CD3 monoclonal antibody in hemophilia A mice
    Thaís B. Bertolini, Roland W. Herzog, Sandeep R. P. Kumar, Alexandra Sherman, Jyoti Rana, Radosław Kaczmarek, Kentaro Yamada, Sreevani Arisa, David Lillicrap, Cox Terhorst et al. · 2023 · Cellular Immunology
  71. Prevention of Type 1 Diabetes in Children: A Worthy Challenge?
    Diletta Maria Francesca Ingrosso, Maria Teresa Quarta, Alessia Quarta, Francesco Chiarelli · 2023 · International Journal of Environmental Research and Public Health
  72. Type 1 diabetes in the pancreas: A histological perspective
    Pia Leete · 2023 · Diabetic Medicine
  73. Novel therapeutic strategies targeting abnormal T-cell signaling in systemic lupus erythematosus
    Masayuki Mizui, Michihito Kono · 2024 · Clinical Immunology
  74. Efficacy of teplizumab for treatment of type 1 diabetes: A meta‐analysis of randomized controlled trials
    Ehsan Heidari, Arman Shafiee, Shahab Noorian, Mohammad Ali Rafiei, Mohammad Reza Abbasi, Mohammad Javad Amini, Omid Safari, Fatemeh Aghamahdi, Mahmood Bakhtiyari · 2024 · Diabetes/Metabolism Research and Reviews
  75. Dépistage et prise en charge du diabète de type 1 préclinique, stade 1–2. Prise de position d’experts français
    Roberto Mallone, Élise Bismuth, Charles Thivolet, Pierre‐Yves Benhamou, Nadine Hoffmeister, François Collet, Marc P Nicolino, Rachel Reynaud, Jacques Beltrand, Jacques Beltrand et al. · 2024 · Médecine des Maladies Métaboliques
  76. Clinical trial data validate the C-peptide estimate model in type 1 diabetes
    John M. Wentworth, Naiara G. Bediaga, Stephen Eric Gitelman, Carmela Evans-Molina, Peter A. Gottlieb, Peter Grahame Colman, Michael J. Haller, Leonard C. Harrison · 2020 · Diabetologia
  77. Assessing effector T cells in type 1 diabetes
    Sefina Arif, Irma Pujol‐Autonell, Martin Eichmann · 2020 · Current Opinion in Endocrinology Diabetes and Obesity
  78. The modulation of mature dendritic cells from patients with type 1 diabetes using human periodontal ligament stem cells. An in-vitro study
    L. Ashour, Rola Al Habashneh, M. M Al-Mrahelh, Duaa Azmi Abuarqoub, Yousef Saleh Khader, Hanan D. Jafar, Abdalla Awidi · 2020 · Journal of Diabetes & Metabolic Disorders
  79. New era of therapy for endocrine autoimmune disorders
    Bergithe Eikeland Oftedal, Anette S. B. Wolff · 2020 · Scandinavian Journal of Immunology
  80. β-cell self-destruction and extremely complicated and still unknown etiopathogenesis of type 1 diabetes
    Artur Chwalba, Aleksandra Pilśniak, Ewa Otto-Buczkowska · 2021 · Pediatric Endocrinology Diabetes and Metabolism
  81. Human Beta Cell Mass Expansion In Vivo With A Harmine and Exendin-4 Combination: Quantification and Visualization By iDISCO+ 3D Imaging
    Carolina Rosselot, Alexandra Alvarsson, Peng Wang, Yansui Li, Kara Beliard, Geming Lu, Rosemary Li, Hongtao Liu, Virginia Gillespie, Nikolaos Tzavaras et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  82. Advances in Islet Transplantation and the Future of Stem Cell–Derived Islets to Treat Diabetes
    Kieffer, Timothy J., Hoesli, Corinne A., Shapiro, A.M. James · 2025 · Cold Spring Harbor Perspectives in Medicine
  83. ENTPD3-specific CAR regulatory T cells for local immune control in T1D
    Tom Pieper, Tobias Riët, Valerie Saetzler, Katharina F. Bergerhoff, Jenny L. McGovern, Louise Delsing, Mark A. Atkinson, Tracey A. Lodie, Lutz Jermutus, Fatih Noyan et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  84. Multiply restimulated human cord blood-derived Tregs maintain stabilized phenotype and suppressive function and predict their therapeutic effects on autoimmune diabetes
    Yuanjie Bi, Ran Kong, Yani Peng, Donghua Cai, Yu Zhang, Fan Yang, Xia Li, Wen Deng, Fang Liu, Binbin He et al. · 2024 · Diabetology & Metabolic Syndrome
  85. Exploring senescence as a modifier of β cell extracellular vesicles in type 1 diabetes
    Roozbeh Akbari Motlagh, Jasmine Pipella, Peter J. Thompson · 2024 · Frontiers in Endocrinology
  86. Anti-CD3 monoclonal antibody in treating patients with type 1 diabetes: an updated systematic review and meta-analysis
    Qi Wu, Rui Wei, Xinyue Liao, Xiaona Cui, Haining Wang, Tianpei Hong · 2025 · Cardiovascular Diabetology
  87. Autoimmune pathogenesis of gestational diabetes mellitus: the risk of progression to type 1 diabetes mellitus
    Milena Skibińska, Marián Kacerovský, Mariusz Grzesiak, Wioletta Izabela Wujcicka · 2025 · Frontiers in Endocrinology
  88. Autoimmune Type 1 Diabetes in the Era of Disease‐Modifying Immune Therapy
    Aaron W. Michels, Peter A. Gottlieb, Bryce Nelson, Colin Mark Dayan · 2025 · Diabetes/Metabolism Research and Reviews
  89. Unraveling Type 1 Diabetes: Integrating Microbiome, Metabolomics, and Immunomodulation for Next-Generation Therapies
    Pleun de Groen, Lente C. H. M. Blok, Coco M. Fuhri Snethlage, Nordin M.J. Hanssen, Elena Rampanelli, Max Nieuwdorp · 2025 · International Journal of Molecular Sciences
  90. Circulating senescence-associated secretory phenotype factors across the stages of type 1 diabetes in a cross-sectional cohort
    Camille Préfontaine, Jasmine Pipella, Ian Heidinger, Nicole Alcasid, Peter J. Thompson · 2025 · Scientific Reports
  91. Immunomodulatory interventions in type 1 diabetes: a systematic review and meta-analysis revealing paradoxical dissociation between beta-cell preservation and glycemic control
    Shankar Kumar Biswas, Bhavya Dhir, Susmitha Talasila, SPURTHY SRI NAMALA, Ankush Kimmatkar, Neeharika Bhamidi, Sudharshan Raajkumar Ezhil, Ummul Barka Safa, Reza Imankhah, Vamsi Priya Sribhashyam et al. · 2025 · BMC Endocrine Disorders
  92. Towards primary prevention of multiple sclerosis
    Ruth Dobson, Karim L. Kreft, Benjamin M. Jacobs, James William L Brown, Alison Thomson, Richard S. Nicholas, Clare Walton, Parth Narendran, on behalf of the UK MS Prevention Taskforce, Tasanee Braithwaite et al. · 2025 · Nature Reviews Neurology
  93. Preclinical stages of Crohn’s disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials
    Dan Turner, Sarah Kenigsberg, Gili Focht, Williams Turpin, Oren Ledder, Anne Marie Griffiths, Hien Quoc Huynh, Л. Л. Плоткин, Yonat Aharoni-Frutkoff, Wael El‐Matary et al. · 2025 · Gut
  94. Advances in Multiple Sclerosis
    Stephen L. Hauser · 2026 · New England Journal of Medicine
  95. The long and winding road: From mouse linkage studies to a novel human therapeutic pathway in type 1 diabetes
    Manuel Rojas, Luke S. Heuer, Weici Zhang, Yi‐Guang Chen, William M. Ridgway · 2022 · Frontiers in Immunology
  96. Screening children for presymptomatic type 1 diabetes
    Lauren Marie Quinn, Rajeeb Rashid, Parth Narendran, David Shukla · 2022 · British Journal of General Practice
  97. Barriers to Screening: An Analysis of Factors Impacting Screening for Type 1 Diabetes Prevention Trials
    Mara Kinney, Lu You, Emily Kristen Sims, Diane K. Wherrett, Desmond Schatz, Sandra M. Lord, Jeffrey P. Krischer, William E. Russell, Peter A. Gottlieb, Ingrid M. Libman et al. · 2023 · Journal of the Endocrine Society
  98. Approval of teplizumab: implications for patients
    Cate Speake, Carla J. Greenbaum · 2023 · Nature Reviews Endocrinology
  99. Post hoc analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders
    Valeria Sordi, Paolo Monti, Vito Lampasona, Raffaella Melzi, Silvia Pellegrini, Bart Keymeulen, Pieter Gillard, Thomas Linn, Emanuele Bosi, Ludger Rose et al. · 2023 · Frontiers in Endocrinology
  100. A 1‐year pilot study of intralymphatic injections of GAD‐alum in individuals with latent autoimmune diabetes in adults (LADA) with signs of high immunity: No safety concerns and resemblance to juvenile type 1 diabetes
    Ingrid Kathrin Hals, Chandima N. D. Balasuriya, Rosaura Casas, Johnny Ludvigsson, Anneli Björklund, Valdemar Grill · 2023 · Diabetes Obesity and Metabolism